Table 1. Baseline clinical characteristics of all patients with AAAD.
| Variable | Platelet count tertiles (×109/L) | P value | |||
|---|---|---|---|---|---|
| T1 (<136) (n=87) | T2 (136 to 184) (n=91) | T3 (>184) (n=90) | |||
| Age (year) | 51.21±9.71 | 50.46±11.16 | 48.21±12.25 | 0.174 | |
| Gender (male) | 69 (79.31) | 62 (68.13) | 58 (64.44) | 0.079 | |
| Laboratory examination pre-operation | |||||
| Neutrophil (×109/L) | 9.64±3.44 | 9.04±3.62 | 9.09±4.29 | 0.510 | |
| Lymphocyte (×109/L) | 1.08±0.57 | 1.18±0.54 | 1.44±0.60 | <0.001* | |
| Hemoglobin (g/L) | 124.40±20.59 | 121.88±18.80 | 119.37±22.69 | 0.273 | |
| APTT (sec) | 36.83±7.02 | 34.53±5.74 | 34.44±6.37 | 0.020* | |
| PT (sec) | 14.83±1.93 | 14.17±2.07 | 14.03±1.46 | 0.009* | |
| Complications | |||||
| Smoking | 41 (47.13) | 42 (46.15) | 40 (44.44) | 0.936 | |
| Drinking | 31 (35.63) | 35 (38.46) | 29 (32.22) | 0.680 | |
| Marfan syndrome | 3 (3.45) | 7 (7.69) | 7 (7.78) | 0.403 | |
| Hypertension | 66 (75.86) | 60 (65.93) | 59 (65.56) | 0.245 | |
| Diabetes mellitus | 6 (6.90) | 5 (5.49) | 2 (2.22) | 0.330 | |
| Hemopericardium | 9 (10.34) | 12 (13.19) | 4 (4.44) | 0.120 | |
| Chronic renal failure | 6 (6.90) | 5 (5.49) | 1 (1.11) | 0.150 | |
| Cerebrovascular disease | 6 (6.90) | 2 (2.20) | 6 (6.67) | 0.279 | |
| Coronary artery disease | 7 (8.05) | 7 (7.69) | 9 (10.00) | 0.838 | |
| Penn class | 0.600 | ||||
| Class Aa | 52 (59.77) | 51 (56.04) | 47 (52.22) | ||
| Non class Aa | 35 (40.23) | 40 (43.96) | 43 (47.78) | ||
| Intra-operative variables | |||||
| Autologous blood transfusion (unit) | 0 (0 to 45) | 0 (0 to 30) | 0 (0 to 30) | 0.448 | |
| Ventilator time (hour) | 6 (0 to 192) | 10 (0 to 960) | 8 (0 to 1,176) | 0.165 | |
| Operative time (hour) | 11.07±3.35 | 11.40±4.31 | 10.18±3.41 | 0.023* | |
| CPB time (min) | 173.86±74.77 | 167.42±70.16 | 147.08±86.45 | 0.057 | |
| Surgery type | 0.174 | ||||
| AAR + TAR (TAVR) + FET | 44 (50.57) | 49 (53.85) | 39 (43.33) | ||
| Bentall + TAR (TAVR) + FET | 14 (16.09) | 25 (27.47) | 19 (21.11) | ||
| David + TAVR + FET | 4 (4.60) | 2 (2.20) | 4 (4.44) | ||
| Combine others | 25 (28.74) | 15 (16.48) | 28 (31.11) | ||
| Perioperative blood transfusion | |||||
| RBCs (unit) | 10.14±7.76 | 9.00±7.47 | 8.29±8.04 | 0.071 | |
| Plasma (unit) | 15.01±10.31 | 12.06±9.28 | 10.45±9.71 | 0.008* | |
| Platelet (therapeutic dose) | 1.57±1.17 | 1.35±1.18 | 1.31±1.45 | 0.047* | |
| Cryoprecipitate (therapeutic dose) | 1.55±1.18 | 1.41±1.27 | 1.28±1.35 | 0.359 | |
| Hospital stay length (day) | 17.52±8.35 | 16.46±8.38 | 17.57±8.84 | 0.617 | |
| ICU stay length (day) | 7.82±6.02 | 7.74±5.97 | 7.01±9.24 | 0.003* | |
| Pneumonia | 42 (48.28) | 38 (41.76) | 19 (21.11) | <0.001* | |
| In-hospital mortality | 14 (16.09) | 14 (15.38) | 8 (8.89) | 0.297 | |
Results are expressed as n (%) or mean ± SD or median (min to max). *, P<0.05. APTT, activated partial thromboplastin time; PT, prothrombin time; CPB, cardiopulmonary bypass; AAR, ascending aorta replacement; TAR, total arch replacement; TAVR, total aortic vascular replacement; FET, frozen elephant trunk; RBC, red blood cell; ICU, intensive care unit.